Commentary|Videos|November 19, 2026

Can Amivantamab Change the HNSCC Landscape?

Fact checked by: Matt Flowers

Ongoing phase 3 research will help clarify the long-term benefit of amivantamab in head and neck squamous cell carcinoma.

The accelerated approval of amivantamab (Rybrevant) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) marks an important development for patients with previously treated disease. However, confirmatory evidence and ongoing clinical trials remain important to establish the treatment's long-term benefit and determine its broader role in the treatment landscape, according to Barbara Burtness, MD, professor of medicine at Yale School of Medicine and medical oncologist at Yale Cancer Center.

In an interview with Targeted Onc.TM, Burtness discusses the ongoing phase 3 OrigAMI-5 trial (NCT06385080), which evaluates amivantamab in combination with carboplatin and pembrolizumab (Keytruda) in the first-line setting for patients with recurrent/metastatic human papillomavirus (HPV)-negative HNSCC. The investigational regimen replaces the second chemotherapy agent in the standard chemotherapy and immunotherapy combination with amivantamab.

Burtness notes that earlier findings from a single-arm cohort demonstrate an objective response rate of approximately 77%, along with encouraging 1-year survival outcomes. The phase 3 study compares this approach with standard doublet chemotherapy plus an immune checkpoint inhibitor. With enrollment approximately halfway complete at the time of the interview, the trial represents an important opportunity to determine whether the investigational combination improves outcomes over the current standard of care.

Burtness also discusses the need for additional research in HPV-associated HNSCC. Although amivantamab demonstrates encouraging activity in HPV-negative disease, the role of EGFR-targeted treatment in HPV-associated cancers remains less established. She anticipates that amivantamab may have a more limited role in this population.

Other investigational approaches may help address this unmet need. Burtness highlights antibody-drug conjugates targeting nectin-4 and B7-H3, which demonstrate promising activity in early research. She also points to the EGFR bispecific antibody petosemtamab, which recently completes a phase 3 trial in first-line recurrent/metastatic disease, with investigators reporting a positive overall survival result.

Although additional data are needed to understand these findings, Burtness emphasizes that ongoing research may expand treatment options across distinct HNSCC populations and further refine the role of targeted therapies.


Related to this article